Jove
Visualize
Contact Us

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.

Lancet (London, England)·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Adjuvant therapy for soft tissue sarcoma.

Scott M Schuetze1, Michael E Ray

  • 1Department of Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA. scotschu@med.umich.edu

Journal of the National Comprehensive Cancer Network : JNCCN
|October 13, 2009
PubMed
Summary

Wide surgical excision is key for localized soft tissue sarcoma. Radiation and chemotherapy can improve outcomes for high-risk patients, particularly those with large or high-grade tumors, reducing recurrence and improving survival.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

  • Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Wide surgical excision is the primary treatment for localized soft tissue sarcoma.
  • Patients with marginal resection, high-grade, or large tumors face increased recurrence risk.

Purpose of the Study:

  • To summarize current therapeutic strategies for soft tissue sarcoma.
  • To identify patient groups who may benefit from specific adjuvant therapies.

Main Methods:

  • Review of established treatment modalities including surgery, radiation, and chemotherapy.
  • Analysis of risk factors for local recurrence and distant disease spread.

Main Results:

  • Radiation therapy (external beam or brachytherapy) reduces local recurrence risk in large (>5 cm) or high-grade sarcomas, especially with incomplete resection.
  • Anthracycline- and ifosfamide-based chemotherapy may improve disease-free and overall survival, particularly for very large (≥10 cm), high-grade extremity sarcomas at high risk for distant recurrence.

Conclusions:

  • Treatment decisions for radiation therapy (preoperative vs. postoperative) require multidisciplinary consultation.
  • Further research is needed to optimize chemotherapy use, treat retroperitoneal sarcomas, and discover novel agents for high-risk soft tissue sarcoma.